European-listed shares of drugmakers Haleon
plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. GSK shares dropped 10% in London, as Sanofi and Haleon also dropped sharply. Analysts at Deutsche Bank said they don’t expect another glyphosate, but “it is very possible we may see a liability of some billions of dollar magnitude incurred.” Analysts at Credit Suisse note Haleon’s prospectus says indemnification “may” include liabilities from Zantac.
Retirees Can Add at Least $100k to Retirement Savings By Doing This
retire and relocateApproximately 80% of all Americans aged 60 and older are homeowners, and housing wealth accounts for about 48%...
Leave a Reply